V. Herceg, S. Adriouach, K. Janikowska, E. Allémann, N. Lange, A. Babič
文献索引:10.1016/j.bioorg.2018.03.020
全文:HTML全文
Treatment of cancer cells by clinically approved hexyl ester of 5-aminolevulinic acid (ALA-Hex) induces accumulation of fluorescent porphyrins in tumors. This allows fluorescence photodiagnosis (PD) of bladder cancer by blue light illumination. However, PD of other cancers is hampered by acute toxicity of the compound limiting its use to local applications. We have designed and synthesized a new prodrug of ALA-Hex that tackles the stability-activity paradox of amino-modified 5-ALA prodrugs. The glucuronide prodrug Glu-ALA-Hex demonstrates excellent stability under physiological conditions and activation in the presence of the target enzyme. β-glucuronidase-triggered release of 5-ALA is programmed to yield fluorescence in tumor environment with elevated β-glucuronidase activity, a characteristic of many solid tumors. Glu-ALA-Hex produces similar levels of fluorescence as ALA-Hex in breast cancer MCF7 cells in vitro but with much lower non-specific cell toxicity.
Design, synthesis, biological evaluation, structure-activity...
2018-04-03 [10.1016/j.bioorg.2018.03.033] |
Synthesis, biological evaluation and molecular docking studi...
2018-04-03 [10.1016/j.bioorg.2018.03.028] |
New advances in synthesis and clinical aspects of pyrazolo[3...
2018-04-03 [10.1016/j.bioorg.2018.03.032] |
Design, synthesis and evaluation of some pyrazolo[3,4-d]pyri...
2018-04-03 [10.1016/j.bioorg.2018.03.030] |
Synthesis and molecular docking study of piperazine derivati...
2018-03-30 [10.1016/j.bioorg.2018.03.026] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved